Key result
Japanese database analysis investigates triple therapy discharge rates for heart failure but lacks abstract results.
Why the study?
There is limited evidence on the extent to which recommended triple combination therapy is currently prescribed to patients with HF at hospital discharge in Japan.
Does triple combination therapy at discharge reduce rehospitalization for HF in Japanese patients across different LVEF subgroups?
Observational
Does triple combination therapy at discharge reduce rehospitalization for HF in Japanese patients across different LVEF subgroups?
Answers are grounded in this paper and cite their sources.
Triple combination therapy is underprescribed at discharge in Japanese patients hospitalized for HF, but its use is associated with a significantly lower risk of 1-year rehospitalization in patients with LVEF <50%.
Background: Triple combination therapy with a renin–angiotensin system modulator, a β-blocker, and a mineralocorticoid receptor antagonist is currently recommended for patients with heart failure (HF) with reduced ejection fraction. However, there is limited evidence on the extent to which triple combination therapy is currently prescribed to patients at the time of discharge from hospital in Japan.
No takes yet. Share an insight, caveat, or question.
Umemura et al. (2023) conducted an observational in Heart failure. Triple combination therapy (renin-angiotensin system modulator, β-blocker, mineralocorticoid receptor antagonist) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: